Search
Nafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360]. … It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigational[A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesZelavespib
go.drugbank.com/drugs/DB12638InvestigationalZelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).
Tetanus immune globulin, human
go.drugbank.com/drugs/DB11604ApprovedInvestigationalTetanus Immune Globulin is manufactured from human plasma [FDA Label]. It contains antibodies against tetanus toxoid and is primarily used as prophylaxis against tetanus in wounded patients.
Categories: Antiinfectives for Systemic UseProducts: GAMMA TET P, TETAGAM PTarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed
Besifloxacin
go.drugbank.com/drugs/DB06771ApprovedBesifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPH-284
go.drugbank.com/drugs/DB05452ExperimentalPH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … PH-284 belongs to a new family of new chemical entities called vomeropherins.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMethylaspartate ammonia-lyase
go.drugbank.com/bio_entities/BE0002760TargetClostridium tetanomorphumInvolved in the methylaspartate cycle. Catalyzes the formation of the alpha,beta-unsaturated bond by the reversible anti elimination of ammonia from L-threo-beta-methylaspartate (L-threo-(2S,3S)-3-methylaspartate) to give mesaconate. It ...
Synonyms: MAL